PA8494501A1 - Sal mutua de amlodipino y atorvastatina - Google Patents

Sal mutua de amlodipino y atorvastatina

Info

Publication number
PA8494501A1
PA8494501A1 PA20008494501A PA8494501A PA8494501A1 PA 8494501 A1 PA8494501 A1 PA 8494501A1 PA 20008494501 A PA20008494501 A PA 20008494501A PA 8494501 A PA8494501 A PA 8494501A PA 8494501 A1 PA8494501 A1 PA 8494501A1
Authority
PA
Panama
Prior art keywords
amlodipino
salt
atorvastatina
mutual salt
mutual
Prior art date
Application number
PA20008494501A
Other languages
English (en)
Inventor
George Chang
Seiichi Hamanaka
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8494501A1 publication Critical patent/PA8494501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA SAL MUTUA DE AMLODIPINO Y ATORVASTATINA, A COMPOSICIONES FARMACEUTICAS DE DICHA SAL Y A PROCEDIMIENTOS DE TRATAMIENTO DE LA ANGINA DE PECHO, LA ATEROSCLEROSIS Y LA HIPERTENSION E HIPERLIPIDEMIA CONJUNTAS, EN LOS MAMIFEROS CON TAL SAL MUTUA Y CON TALES COMPOSICIONES. ESTA INVENCION TAMBIEN SE REFIERE A PROCEDIMIENTOS DE TRATAMIENTO DEL RIESGO CARDIACO EN UN MAMIFERO QUE PRESENTA SINTOMAS DE RIESGO CARDIACO, INCLUYENDO LOS SERES HUMANOS, MEDIANTE LA ADMINISTRACION DE TAL SAL MUTUA Y DE TALES COMPOSICIONES.
PA20008494501A 1999-05-27 2000-04-25 Sal mutua de amlodipino y atorvastatina PA8494501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626999P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
PA8494501A1 true PA8494501A1 (es) 2002-07-30

Family

ID=22472108

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20008494501A PA8494501A1 (es) 1999-05-27 2000-04-25 Sal mutua de amlodipino y atorvastatina

Country Status (36)

Country Link
US (1) US6262092B1 (es)
EP (1) EP1180097B1 (es)
JP (1) JP2003500473A (es)
KR (1) KR20020019450A (es)
CN (1) CN1373753A (es)
AP (1) AP2001002347A0 (es)
AR (1) AR028994A1 (es)
AT (1) ATE367376T1 (es)
AU (1) AU4138200A (es)
BG (1) BG106128A (es)
BR (1) BR0011008A (es)
CA (1) CA2375225C (es)
DE (1) DE60035581T2 (es)
EA (1) EA200101132A1 (es)
EE (1) EE200100632A (es)
ES (1) ES2287009T3 (es)
GT (1) GT200000077A (es)
HN (1) HN2000000050A (es)
HR (1) HRP20010857A2 (es)
HU (1) HUP0202070A3 (es)
IL (1) IL145837A0 (es)
IS (1) IS6133A (es)
MA (1) MA26739A1 (es)
MX (1) MXPA01012126A (es)
NO (1) NO20015757L (es)
OA (1) OA11951A (es)
PA (1) PA8494501A1 (es)
PE (1) PE20010168A1 (es)
PL (1) PL352828A1 (es)
SK (1) SK16802001A3 (es)
TN (1) TNSN00110A1 (es)
TR (1) TR200103411T2 (es)
UA (1) UA56363C2 (es)
UY (1) UY26163A1 (es)
WO (1) WO2000073271A1 (es)
ZA (1) ZA200109693B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU2001283085A1 (en) * 2000-08-04 2002-02-18 R. Preston Mason Synergistic effect of amlodipine and atorvastatin
US20050119270A1 (en) * 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
CN1152013C (zh) * 2001-11-22 2004-06-02 张喜田 一类左旋氨氯地平盐的水合物及其制剂
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AU2007300071A1 (en) * 2006-09-27 2008-04-03 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
US20090042849A1 (en) * 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
JP2018516624A (ja) * 2015-04-15 2018-06-28 コンシーヴァルブ エルエルシー 自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法
CN105012258B (zh) * 2015-08-06 2017-11-03 北京嘉林药业股份有限公司 阿托伐他汀钙和氨氯地平片剂的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
NO20015757D0 (no) 2001-11-26
IL145837A0 (en) 2002-07-25
BR0011008A (pt) 2002-02-19
BG106128A (en) 2002-05-31
CA2375225C (en) 2007-02-20
CN1373753A (zh) 2002-10-09
EE200100632A (et) 2003-02-17
TNSN00110A1 (fr) 2005-11-10
AU4138200A (en) 2000-12-18
TR200103411T2 (tr) 2002-04-22
KR20020019450A (ko) 2002-03-12
DE60035581D1 (de) 2007-08-30
HRP20010857A2 (en) 2003-02-28
ES2287009T3 (es) 2007-12-16
AP2001002347A0 (en) 2001-12-31
MA26739A1 (fr) 2004-12-20
AR028994A1 (es) 2003-06-04
MXPA01012126A (es) 2002-06-04
UY26163A1 (es) 2000-12-29
JP2003500473A (ja) 2003-01-07
UA56363C2 (uk) 2003-05-15
EA200101132A1 (ru) 2002-04-25
ATE367376T1 (de) 2007-08-15
DE60035581T2 (de) 2008-04-17
PL352828A1 (en) 2003-09-08
HUP0202070A3 (en) 2003-03-28
EP1180097A1 (en) 2002-02-20
HUP0202070A2 (en) 2002-10-28
HN2000000050A (es) 2001-02-02
EP1180097B1 (en) 2007-07-18
GT200000077A (es) 2001-11-16
PE20010168A1 (es) 2001-02-10
OA11951A (en) 2006-04-13
NO20015757L (no) 2001-12-20
WO2000073271A1 (en) 2000-12-07
US6262092B1 (en) 2001-07-17
IS6133A (is) 2001-10-30
CA2375225A1 (en) 2000-12-07
SK16802001A3 (sk) 2003-02-04
ZA200109693B (en) 2002-11-26

Similar Documents

Publication Publication Date Title
PA8494501A1 (es) Sal mutua de amlodipino y atorvastatina
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
GT199800127A (es) Combinaciones terapeuticas.
DK1079806T3 (da) Præparater til påföringen af antiinflammatoriske, især antiseptiske midler og/eller midler, der fremmer helingen af sår, til de övre luftveje og/eller öret
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
AR018143A1 (es) Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca
ATE514418T1 (de) Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
NO20062198L (no) Bradykinin B1 reseptorantagonister
PA8457201A1 (es) Terapias de combinacion
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
GT200000078A (es) Profarmacos mutuos de amlodipino y atorvastatina.
JP2005511619A5 (es)
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
ES2164447T3 (es) Procedimiento de inhibicion de resorcion del hueso.
DK1502586T3 (da) Anvendelse af desinficerende midler ved fremstillingen af en farmaceutisk sammensætning til forebyggelsen eller behandlingen af inflammationer i det indre af menneskekroppen
DK1035859T3 (da) Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler
CA2385755A1 (en) Prevention of colorectal cancer
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
DK1478362T3 (da) Kombinationsbehandling til akut myokardisk infarkt
PA8494201A1 (es) Efectos sinergeticos de amlodipino y atorvastatina o metabolito de atorvastatina como una base para terapia de combinacion
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
WO2006117404A3 (de) Topische verwendung von radikalfangenden substanzen zur antipyretischen behandlung
AR029451A1 (es) Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia
PA8496801A1 (es) Complejo farmaceutico
DK1276477T3 (da) Medikamenter indeholdende pantothensyre til behandlingen af inflammatorisk ledsygdom